Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Gene expression in brain during cuprizone-induced demyelination and remyelination.
Sex ratio of multiple sclerosis and clinical phenotype.
Synthetic Biologics Reports UCLA Announcement of Preliminary Positive Topline Efficacy and Safety Results from Investigator-Led Phase II Study of Trimesta™ for RRMS
Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System.
IL-17 and Th17 Cells.
HLA-DRB1*15:01 and multiple sclerosis: a female association?
Clinically isolated syndrome - Rethinking the diagnosis.
T(H)17 cytokines in autoimmune neuro-inflammation.
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study.
[Usefulness of electronic drug registers: Spanish register of patients treated with fingolimod (Gilenya ®)].
Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
The MS Microbiome Consortium (MSMC): an academic multi-disciplinary collaborative effort to elucidate the role of the gut microbiota in MS
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
Therapeutic plasma exchange and pregnancy: A case report and guidelines for performing plasma exchange in a pregnant patient.
Neuroprotection mediated through estrogen receptor-alpha in astrocytes.
Best practice in the use of natalizumab in multiple sclerosis.
Management of worsening multiple sclerosis with mitoxantrone: a review.
Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair
Birth Outcomes in Newborns Fathered by Men with Multiple Sclerosis Exposed to Disease-Modifying Drugs.
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort.
Teriflunomide modest help but safe for MS
Suppressed RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis.

Pages